Loading...
XKRX
011000
Market cap119mUSD
Dec 05, Last price  
2,070.00KRW
1D
-0.24%
1Q
-15.85%
Jan 2017
-63.05%
Name

Gene One Life Science Inc

Chart & Performance

D1W1MN
XKRX:011000 chart
P/E
—
P/S
4.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.22%
Rev. gr., 5y
-2.83%
Revenues
35.72b
-11.15%
10,090,159,00013,974,021,00015,003,954,00023,281,689,00027,737,197,30019,410,461,05020,657,215,57024,625,225,86028,364,784,67031,371,459,15027,171,385,67034,292,567,64041,241,251,46041,502,728,97038,700,355,31048,718,300,17040,202,911,10035,720,099,000
Net income
-48.54b
L-37.59%
-2,902,726,000-5,849,328,000-8,415,948,000-7,592,468,000-4,937,077,000-8,888,478,000-8,362,870,000-6,491,730,0001,413,762,890-15,598,929,630-23,729,654,920-11,897,642,780-7,618,562,790-18,648,412,110-15,951,499,510-38,150,069,800-77,768,041,880-48,536,607,000
CFO
-16.06b
L-26.15%
-3,269,203,000-3,147,292,000-3,040,938,000-3,876,427,000-2,874,458,200-6,202,869,980-2,347,273,130-4,158,524,800778,497,730-12,388,731,200-4,040,042,510-7,268,957,370-1,270,007,140-15,915,810,140-4,849,167,610-24,113,048,350-21,743,560,700-16,058,108,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
URL
https://www.genels.com/
IPO date
Nov 16, 1987
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT